Andrew Niewiarowski

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIMS To compare the pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a biosimilar of adalimumab, with European Union (EU)-approved Humira and US-licensed Humira after single subcutaneous doses in healthy subjects. METHODS In a randomized, double-blind, parallel-group study, 180 healthy subjects received by subcutaneous injection 40 mg(More)
  • 1